Insulet (PODD) Investor presentation summary

Market position and scale

• Omnipod 5 is the first AID system FDA-cleared for both type 1 and type 2 diabetes in the U.S.; ranked #1 in U.S. requested and prescribed AID systems and new customer starts.

• 2025 scale: $2.7B revenue, 600K+ active customers and presence in 26 global markets.

• AID market growth from 2020–25: 66% driven by Insulet; Omnipod had 66% of 2025 new customer starts and was nearing 50% of global AID revenue share.

• U.S. Omnipod revenue grew at a 31% CAGR from 2021–25; international revenue grew at a 20% CAGR over the same period.

Financial performance

• Revenue rose from $1.1B in 2021 to $2.7B in 2025, representing a 25% CAGR.

• Adjusted operating margin increased from 11.5% in 2021 to 17.6% in 2025; adjusted diluted EPS rose from $0.86 to $4.97.

• Free cash flow increased from negative $180M in 2021 to $378M in 2025.

Market opportunity

• Addressable market today is stated at $30B+ across ~8M people with diabetes; the AID market is ~$6B today, with a path to ~$9B by 2028.

• Growth opportunities include U.S. T2D basal-only, T2D outside the U.S., and additional T1D markets in Asia.

• U.S. T1D penetration target: 50–55% by 2028, versus ~40% today; U.S. T2D target: 10–15%, versus ~5% today.

• International T1D penetration target: 30–35% by 2028, versus ~25% today.